{
    "2019-03-21": [
        [
            {
                "time": "2019-03-21",
                "original_text": "Biogen’s Big Bet in Alzheimer’s Disease Is a Bust",
                "features": {
                    "keywords": [
                        "Biogen",
                        "Alzheimer’s",
                        "Bust"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-15",
                "original_text": "Alkermes Focuses on Pipeline, Depends on Partners for Funds",
                "features": {
                    "keywords": [
                        "Alkermes",
                        "Pipeline",
                        "Partners",
                        "Funds"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-03-21",
                "original_text": "Biogen shares tank nearly 30% after pulling key Alzheimer’s drug trial",
                "features": {
                    "keywords": [
                        "Biogen",
                        "shares",
                        "tank",
                        "Alzheimer’s",
                        "drug",
                        "trial"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-03-20",
                "original_text": "9 High-Margin Stocks Seen Leading in Fed's New Dovish Era",
                "features": {
                    "keywords": [
                        "High-Margin",
                        "Stocks",
                        "Fed",
                        "Dovish",
                        "Era"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "economy",
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}